Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes, Depression
Cognitive Behavioral Therapy for Adherence in Patients With Type 2 Diabetes
Despite the significant relationship between depression and diabetes, there are few published studies testing the effect of cognitive behavioral therapy in improving disease outcomes among diabetics in primary healthcare settings…
- Trial name
- NCT04214600
- Testing
- Cognitive Behavioral Therapy (CBT)
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Cairo University
Diabetes Mellitus Type 2
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients…
- Trial name
- NCT02373865
- Testing
- Sitagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- GWT-TUD GmbH
Diabetes
Point-of-Care Glucose Testing and Insulin Supplementation
Capillary point-of-care (POC) testing is advocated as a valuable aid in the management of diabetes and hyperglycemia in the hospital setting.
- Trial name
- POC (NCT01702311)
- Testing
- Bedtime insulin Aspart (Novolog)
- Where
- 2 sites in United States
- Volunteers
- 235 people
- Sponsor
- Emory University
Type 2 Diabetes Mellitus, Heart Failure
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes…
- Trial name
- MEASURE-HF (NCT02917031)
- Testing
- Saxagliptin, Sitagliptin
- Where
- 74 sites in United States, Bulgaria and 8 more
- Volunteers
- 348 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome
Among adult individuals with type 2 diabetes mellitus and at risk for heart failure with impaired relaxation of the heart mildly reduced kidney filtration function (Type 4 cardiorenal syndrome) this trial will evaluate the…
- Conditions
- Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
- Trial name
- NCT02251431
- Testing
- BYDUREON
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Baylor Research Institute
Diabetes Mellitus, Type 2
An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes
The purpose of this study is to identify specific patient, physician, and health system related factors associated with the progression to a more intensive regimen from initial insulin therapy for patients with type 2 diabetes.
- Trial name
- MOSAIc (NCT01400971)
- Where
- 153 sites in United States, Argentina and 17 more
- Volunteers
- 4,299 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
Study will evaluate if a combination of saxagliptin and dapagliflozin added concurrently to metformin in combination with diet and exercise is superior to sitagliptin added to metformin in combination with diet and exercise in…
- Trial name
- NCT02284893
- Testing
- Saxagliptin, Dapagliflozin, Sitagliptin
- Where
- 79 sites in United States, Hungary and 4 more
- Volunteers
- 461 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications
Primary Objective: To demonstrate the non-inferiority of H0E901-U300 to Lantus, in change of glycated hemoglobin A1c (HbA1c). Secondary Objectives: To demonstrate the superiority of H0E901-U300 in comparison with Lantus in…
- Trial name
- SENIOR (NCT02320721)
- Testing
- Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
- Where
- 162 sites in United States, Argentina and 16 more
- Volunteers
- 1,014 people
- Sponsor
- Sanofi
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes
The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo.
- Trial name
- NCT00993824
- Testing
- colesevelam HCl
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- HealthPartners Institute
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Psoriasis, Type 2 Diabetes Mellitus
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.
The primary purpose of this study is to determine if sitagliptin (Januvia®) improves psoriasis severity after 16 weeks of treatment in 20 participants with both psoriasis and type 2 diabetes mellitus.
- Trial name
- DIP (NCT01991197)
- Testing
- Sitagliptin, Gliclazide
- Where
- 2 sites in Ireland
- Volunteers
- 20 people
- Sponsor
- University College Dublin
Coronary Artery Disease, Type 2 Diabetes Mellitus
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes.
- Trial name
- NCT00818779
- Testing
- Aliskiren, Amlodipine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Texas Tech University Health Sciences Center
Peripheral Artery Disease, Type 2 Diabetes
Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes
The hypothesis being that both aspirin-ticagrelor and ticagrelor monotherapy will be superior to aspirin monotherapy in the reduction of whole blood viscosity at the end of each 4 week treatment period.
- Trial name
- NCT02325466
- Testing
- Aspirin, Ticagrelor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Type 2 Diabetes Mellitus
An Efficacy, Safety, and Tolerability Study for TA-7284 in Patients With Type 2 Diabetes
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of TA-7284 compared with placebo in patients with type 2 diabetes.
- Trial name
- NCT01022112
- Testing
- TA-7284-Low, TA-7284-Low-middle, TA-7284-High-middle
- Where
- 6 sites in Japan
- Volunteers
- 383 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of CJC-1134-PC in Patients With Type 2 Diabetes Who Are Currently on Metformin Monotherapy
This is a multicenter, randomized, placebo-controlled, double-blind, Phase II study. The objective of this study is to evaluate the efficacy and safety of 12 weeks of treatment with CJC-1134-PC in patients who are currently on…
- Trial name
- NCT00674466
- Testing
- 1.5 mg or 2.0 mg CJC-1134-PC
- Where
- Canada
- Volunteers
- 90 people
- Sponsor
- ConjuChem
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
- Trial name
- NCT00998881
- Testing
- Teneligliptin 20 mg
- Where
- Japan
- Volunteers
- 203 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes, Obesity
Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
The purpose of this study is to determine whether the GI Sleeve is safe and effective in treating Type II diabetes patients
- Trial name
- NCT00791128
- Testing
- GI Liner
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-S (NCT03770728)
- Testing
- Efpeglenatide SAR439977, Background therapy: Metformin alone or in combination with SU
- Where
- 48 sites in United States, China and 1 more
- Volunteers
- 312 people
- Sponsor
- Sanofi